Cite
HARVARD Citation
Zimmer, L. et al. (2020). Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 395 (10236), pp. 1558-1568. [Online].